

April 25, 2013



Navidea Biopharmaceuticals to Present at the Needham 12th Annual Healthcare Conference

– Chief Executive Officer to Provide Business and Development Program Updates –

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, President and Chief Executive Officer, will participate at the Needham 12th Annual Healthcare Conference on April 30 - May 1, 2013 at the Westin Grand Central Hotel, New York City. Dr. Pykett will provide an update of the Company and its development programs on Wednesday, May 1, 2013 at 3:40 PM EDT.

Investors and the public are invited to listen to a live webcast of Dr. Pykett's presentation at <http://wsj.com/webcast/needham58/navb/>. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek[®], NAV4694, NAV5001 and RIGScan[™] – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Brent Larson, Sr. VP & CFO
(614) 822-2330

Source: Navidea Biopharmaceuticals, Inc.